# GENERAL INFORMATION

Meeting: 5<sup>th</sup> Euro VT/VF Meeting 2013

Date: 6./7. December 2013

### Scientific Committee:

K.-H. Kuck, Hamburg (DE), P. Della Bella, Milan (IT) G. Hindricks, Leipzig (DE), P. Jais, Bordeaux (FR)

#### Venue:

Grand Hyatt Berlin

Marlene-Dietrich-Platz 2, D-10785 Berlin

Tel.: +49 (0) 30 25 53 12 34, Fax: +49 (0) 30 25 53 12 35

E-Mail: berlin.grand@hyatt.com, www.berlin.grand.hyatt.com

Language: The official conference language is English.

### Registration fee:

By 15. Oct., 2013: € 485,—, From 16. Oct., 2013: € 600,—

Registration fee includes:

- Admission to the Scientific sessions
- Congress Material
- Coffee breaks & Lunch
- Certificate of attendance

Online registration: www.euro-vtvf.eu

### Organizer:

Prof. Dr. Karl-Heinz Kuck
Euro EP uG
c/o Asklepios Klinik St. Georg
Lohmühlenstraße 5, D-20099 Hamburg
Tel.: +49 (0) 40 18 18-85 23 08, Fax: +49 (0) 40 18 18-85 44 44

E-Mail: k.kuck@asklepios.com, www.asklepios.com

### Congress Agency:

## wkonect

wikonect GmbH

Hagenauer Straße 53, D-65203 Wiesbaden

Tel.: +49 (0) 611 204809-0, Fax: +49 (0) 611 204809-10

E-Mail: info@wikonect.de, www.wikonect.de





The meeting is accredited by:
The European Board of Accreditation in Cardiology







Partner:











### PREFACE

Dear colleagues, Dear friends,

Encouraged by the great success of the last four meetings, we will be convening the 5<sup>th</sup> Euro VT/VF Meeting on 6./7. December 2013 in Berlin. We would like to cordially invite you to attend our meeting.

The first treatment of ventricular tachycardia by open heart surgery in the early 1980's and by percutaneous catheter procedures, using first DC Shock and later radiofrequency, current in the mid 1980's is almost more than 30 years ago. The experience was limited to patients with life-threatening ventricular tachycardia refractory to medical treatment. These procedures were performed in a few centers around the world by only very experienced physicians.

The introduction of the implantable defibrillator by Michel Mirowski substantially changed the treatment of VT/VF and made catheter ablation a procedure, which in many countries was mostly performed in patients following multiple ICD interventions. In most patients without structural heart disease new mechanistic insights based on catheter ablation procedures made catheter ablation a first line treatment.

Following the enthusiasm in catheter ablation of atrial fibrillation new interests of physicians and industry has initiated an upcoming revival of ventricular tachycardia / fibrillation treatment beyond the ICD. This has led to new studies in the field of ICD and CRT but also of catheter ablation including preventive ablation procedures in ICD patients. Further interest has also been stimulated by the use of diagnostic tools such as MRI, allowing better understanding of the underlying substrate.

The 5<sup>th</sup> EURO VT/VF symposium in Berlin, Germany, will address the entire field of VT/VF from genetics, mechanisms, diagnostics to therapeutics by bringing international physicians together.

We hope that this meeting will find your interest and we look forward to seeing you in Berlin.

K.-H. Kuck

P. Della Bella

G. Hindricks

P. Jais



8:30	Welcome and introduction KH. Kuck, Germany
	I. Session: CIEDs for the next decade: what's to come Chairs: C. Leclerque, France; W. T. Abraham, USA*
8:45	<b>Leadless Pacing</b> J. Sperzel, Germany
9:05	Subcutaneous ICD D. A. Theuns, Netherlands
9:25	Novel electrical device concepts for heart failure W. T. Abraham, USA*
9:45	Role of novel implantable devices for disease management programs G. Boriani, Italy
	II. Session Chairs: C. Israel, Germany; W. Zareba, USA
10:05	ICD implantation in patients with the potential to improve LV function. How long to wait for the ICD and how to bridge?  C. Wolpert, Germany
10:25	Why should the ICD not help in patients with an EF > 35 %? W. Zareba, USA
10:45	Why does DFT testing not increase mortality when spontaneous ICD shocks do?  D. Bänsch, Germany
11:05	Do patients with high DFT's die more often than patients with normal DFT's? H. Heidbuchel, Belgium

### 11:25 – 11:45 Coffee Break

III. Session: Device-related complications: incidence, diagnosis and treatment

Chairs: C. Blomström-Lundquist, Sweden; M. Bongiorni, Italy

11:45	Device-related complications in the real world: Data from the National Danish Registry J. Cosedis Nielson, Denmark*
12:05	Improved work flow for device implantation to reduce complications S. Richter, Germany
12:25	Device infections – Antibiotic treatment and re-implantation: How and when? C. Israel, Germany
12:45	Special Lecture: Lead extraction 2013 – State of the Art M. Bongiorni, Italy

	13:05 – 14:05 Lunch
	IV. Session: CIEDS in 2013: Current status and news from recent trials Chairs: S. Hohnloser, Germany; P. Brugada, Belgium*
	Novel data from recent trials:
4:05	BLOCK HF A. Curtis, USA
4:25	IN TIME G. Hindricks, Germany
4:45	<b>ECHO-CRT</b> F. Ruschitzka, Switzerland
5:05	SMS KH. Kuck, Germany

	15:25 – 15:45 Coffee Break
	V. Session: The autonomic nervous system and VT/V Chairs: H. Kottkamp, Switzerland; P. Schwartz, Italy
15:45	Special Lecture: Interaction of the ANS and VT/VF K. Shivkumar, USA
16:05	Non-Pharmacological modulation of the ANS to prevent VT/VF P. Schwartz, Italy
16:25	Left Cardiac Sympathetic Denervation Therapy for Malignant VF Syndromes M. Ackermann, USA

16:45 Device based modulation of the ANS to prevent VT/VF

P. Schauerte, Germany

17:05	<b>Catheter ablation of sympathetic drive to prevent VT/VF</b> V. Reddy, USA
	VI. Session: Sports in patients with arrhythmogenic conditions Chairs: D. Corrado, Italy
17:25	– in patients with HOCM/HCM W. Mc Kenna, United Kingdom
17:45	<ul><li>in patients with channelopathies</li><li>P. Brugada, Belgium</li></ul>
18:05	– in patients with ARVD H. Heidbuchel, Belgium
18:25	– in patients with ICD D. Corrado, Italy
	SATURDAY

	VII. Session: In Focus: Catheter ablation of VT post MI and in DCM Chairs: P. Della Bella, Italy; P. Jais, France
8:30	The substrate of VT in DCM and post MI F. Bogun, USA
8:50	Ablation of ischemic VT: techniques and outcome W. G. Stevenson, USA
9:10	Ablation of VT in DCM: techniques and outcome H. Kottkamp, Switzerland

### 9:30 – 9:50 Coffee Break VIII. Session: New mapping and ablation technologies for the treatment of VT/VF Chairs: G. Hindricks, Germany; M. Hutchinson, USA Body surface mapping of VT/VF

	P. Jais, France
10:10	Rapid Mapping with a new multipolar electrode system H. Nakagawa, USA
10.30	Manning of late ventricular activation

P. Della Bella, Italy

10:50	MRI-guided mapping and ablation of VT/VF C. Piorkowski, Germany
11:10	Transcutaneous ablation of VT/VF A. Al-Ahmad, USA
11:30	Pace mapping during sinus rhythm C. De Chillou, France

11:30	Pace mapping during sinus rhythm C. De Chillou, France
	11:50 – 12:50 Lunch
	IX. Session: In Focus: Epicardial mapping and ablation
	Chairs: KH. Kuck, Germany; W. Stevenson, USA
12:50	Special Lecture: Indications for epicardial ablation: when first line, when second line and when surgical access?  M. Hutchinson, USA
13:10	<b>Techniques for safe percutaneous epicardial access</b> R. Tilz, Germany
13:30	Complications: recognition and treatment A. D'Avila, USA
13:50	Epicardial mapping and interpretation of epicardial electrograms K. Zeppenfeld, Netherlands
14:10	Surgical access to the epicardium: when and how? S. Benussi, Italy
	X. Session: Catheter ablation of VT/VF in rare entities Chairs: J. Atie, Brasil; H. Nakagawa, USA
14:30	Congential heart disease K. Zeppenfeld, Netherlands
14:50	Acquired valvular heart disease A. Arya, Germany
15:10	<b>Myocarditis</b> G. Maccabelli, Italy

Idiopathic ventricular fibrillation



P. Jais, France

15:50 Adjourn\*

<sup>\*</sup>requested but no commitment